Biopeutics has a product portfolio of drugs
of known clinical characteristics.
These products have been on the market for
years and their safety is well established and documented. Based on the vast
experience and knowledge of using these products, Biopeutics
is developing new clinical indications
for cardiovascular dysfunctions.
This model allows us to save
time, reduce cost and lower risk for new product development.
Biopetuics is developing various
ranges of products to treat cardiovascular problems and
peripheral arterial occlusive disease.
Biopeutics is currently focusing on developing treatments for chronic heart failure,
since this is one of the most challenging diseases, with
in its advanced stage.
Biopeutics currently has three clinical-stage
products with a further one in animal-testing stage and
also has two new delivery methods in our R&D
Our goal is to become a leading R&D company in the cardiovascular field.